Androgen receptor corepressors and prostate cancer

Endocrine-Related Cancer

Volumn 13, Issue 4, 2006, Pages 979-994

  Burd, Craig J ^a   Morey, Lisa M ^a   Knudsen, Karen E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CALRETICULIN; COLECALCIFEROL RECEPTOR; CYCLIN D1; CYPROTERONE ACETATE; DAXX PROTEIN; DNA BINDING PROTEIN; FILAMIN A; FOCAL ADHESION KINASE 2; FORKHEAD TRANSCRIPTION FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; MIFEPRISTONE; NUCLEAR RECEPTOR COACTIVATOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN SMRT; PROTEIN TYROSINE PHOSPHATASE SHP 1; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CHROMATIN CONDENSATION; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HORMONE ACTION; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS;

EID: 33846815520     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01115     Document Type: Review

References (142)

1. Agoulnik IU, Krause WC, Bingman WE, III, Rahman HT, Amrikachi M, Ayala GE & Weigel NL 2003 Repressors of androgen and progesterone receptor action. Journal of Biological Chemistry 278 31136-31148.
2. Agoulnik IU, Vaid A, Bingman WE, III, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM & Weigel NL 2005 Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Research 65 7959-7967.
3. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW & Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of the National Cancer Institute 91 1869-1876.
4. Alen P, Claessens F, Verhoeven G, Rombauts W & Peeters B 1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Molecular and Cellular Biology 19 6085-6097.
5. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N & DePinho RA 1997 Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387 49-55.
6. Altomare DA & Testa JR 2005 Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 7455-7464.
7. Bai S, He B & Wilson EM 2005 Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Molecular and Cellular Biology 25 1238-1257.
8. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL & Parker MG 2005 Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Molecular and Cellular Biology 25 1425-1436.
9. Berrevoets CA, Doesburg P, Steketee K, Trapman J & Brinkmann AO 1998 Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Molecular Endocrinology 12 1172-1183.
10. Berrevoets CA, Umar A, Trapman J & Brinkmann AO 2004 Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR). Biochemical Journal 379 731-738.
11. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA & Trapman J 1999 Mechanisms of androgen receptor activation and function. Journal of Steroid Biochemistry and Molecular Biology 69 307-313.
12. Burd CJ, Petre CE, Moghadam H, Wilson EM & Knudsen KE 2005 Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Molecular Endocrinology 19 607-620.
13. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES et al. 2006 Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. PNAS 103 2190-2195.
14. Callewaert L, Van Tilborgh N & Claessens F 2006 Interplay between two hormone-independent activation domains in the androgen receptor. Cancer Research 66 543-553.
15. Chen G, Nomura M, Morinaga H, Matsubara E, Okabe T, Goto K, Yanase T, Zheng H, Lu J & Nawata H 2005 Modulation of androgen receptor transactivation by FoxH1. A newly identified androgen receptor corepressor. Journal of Biological Chemistry 280 36355-36363.
16. Cheng S, Brzostek S, Lee SR, Hollenberg AN & Balk SP 2002 Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Molecular Endocrinology 16 1492-1501.
17. Cinar B, Yeung F, Konaka H, Mayo MW, Freeman MR, Zhau HE & Chung LW 2004 Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochemical Journal 379 421-431.
18. Coqueret O 2002 Linking cyclins to transcriptional control. Gene 299 35-55.
19. Cronauer MV, Schulz WA, Burchardt T, Ackermann R & Burchardt M 2004 Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23 3541-3549.
20. Culig Z, Comuzzi B, Steiner H, Bartsch G & Hobisch A 2004 Expression and function of androgen receptor coactivators in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 92 265-271.
21. Dedhar S, Rennie PS, Shago M, Hagesteijn CY, Yang H, Filmus J, Hawley RG, Bruchovsky N, Cheng H, Matusik RJ et al. 1994 Inhibition of nuclear hormone receptor activity by calreticulin. Nature 367 480-483.
22. Denmeade SR & Isaacs JT 2002 A history of prostate cancer treatment. Nature Reviews Cancer 2 389-396.
23. Denmeade SR, Lin XS & Isaacs JT 1996 Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28 251-265.
24. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C & Pandolfi PP 2001 Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nature Genetics 27 222-224.
25. Diehl JA, Cheng M, Roussel MF & Sherr CJ 1998 Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes & Development 12 3499-3511.
26. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA & Baniahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Molecular Endocrinology 16 661-673.
27. Dreher T, Zentgraf H, Abel U, Kappeler A, Michel MS, Bleyl U & Grobholz R 2004 Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Archiv 444 509-517.
28. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240 889-895.
29. Feldman BJ & Feldman D 2001 The development of androgen-independent prostate cancer. Nature Reviews Cancer 1 34-45.
30. Fu M, Wang C, Wang J, Zafonte BT, Lisanti MP & Pestell RG 2002a Acetylation in hormone signaling and the cell cycle. Cytokine & Growth Factor Reviews 13 259-276.
31. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA, Jaffray E et al. 2002b Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Molecular and Cellular Biology 22 3373-3388.
32. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C et al. 2003 Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Molecular and Cellular Biology 23 8563-8575.
33. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A & Chang C 1999 Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. Journal of Biological Chemistry 274 8316-8321.
34. Fujimoto N, Mizokami A, Harada S & Matsumoto T 2001 Different expression of androgen receptor coactivators in human prostate. Urology 58 289-294.
35. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015.
36. Gobinet J, Auzou G, Nicolas JC, Sultan C & Jalaguier S 2001 Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP. Biochemistry 40 15369-15377.
37. Gottschalk AR, Basila D, Wong M, Dean NM, Brandts CH, Stokoe D & Haas-Kogan DA 2001 p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Research 61 2105-2111.
38. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 5718-5724.
39. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS & Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 61 4315-4319.
40. Gross M, Liu B, Tan J, French FS, Carey M & Shuai K 2001 Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene 20 3880-3887.
41. Gross M, Yang R, Top I, Gasper C & Shuai K 2004 PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 23 3059-3066.
42. Gumerlock PH, Chi SG, Shi XB, Voeller HJ, Jacobson JW, Gelmann EP & deVere White RW 1997 p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. Journal of the National Cancer Institute 89 66-71.
43. Halvorsen OJ, Haukaas SA & Akslen LA 2003 Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research 9 1474-1479.
44. He B, Kemppainen JA & Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. Journal of Biological Chemistry 275 22986-22994.
45. He B, Bowen NT, Minges JT & Wilson EM 2001 Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. Journal of Biological Chemistry 276 42293-42301.
46. He B, Minges JT, Lee LW & Wilson EM 2002 The FXXLF motif mediates androgen receptor-specific interactions with coregulators. Journal of Biological Chemistry 277 10226-10235.
47. He B, Gampe RT, Jr, Hnat AT, Faggart JL, Minges JT, French FS & Wilson EM 2006 Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. Journal of Biological Chemistry 281 6648-6663.
48. Heinlein CA & Chang C 2002 Androgen receptor (AR) coregulators: an overview. Endocrine Reviews 23 175-200.
49. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR et al. 1997 A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387 43-48.
50. Hill R, Song Y, Cardiff RD & Van Dyke T 2005 Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Research 65 10243-10254.
51. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC. Choi E, Balk SP & Hollenberg AN 2005 The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. Journal of Biological Chemistry 280 6511-6519.
52. Holter E, Kotaja N, Makela S, Strauss L, Kietz S, Janne OA, Gustafsson JA, Palvimo JJ & Treuter E 2002 Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1. Molecular Endocrinology 16 515-528.
53. Hu YC, Yeh S, Yeh SD, Sampson ER, Huang J, Li P, Hsu CL, Ting HJ, Lin HK, Wang L et al. 2004 Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. Journal of Biological Chemistry 279 33438-33446.
54. Ikonen T, Palvimo JJ & Janne OA 1997 Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. Journal of Biological Chemistry 272 29821-29828.
55. Iso T, Sartorelli V, Chung G, Shichinohe T, Kedes L & Hamamori Y 2001 HERP, a new primary target of Notch regulated by ligand binding. Molecular and Cellular Biology 21 6071-6079.
56. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C & Thun MJ 2006 Cancer statistics. CA: A Cancer Journal for Clinicians 56 106-130.
57. Jenster G 1998 Coactivators and corepressors as mediators of nuclear receptor function: an update. Molecular and Cellular Endocrinology 143 1-7.
58. Jenster G 1999 The role of the androgen receptor in the development and progression of prostate cancer. Seminars in Oncology 26 407-421.
59. Jenster G, van der Korput JA, Trapman J & Brinkmann AO 1992 Functional domains of the human androgen receptor. Journal of Steroid Biochemistry and Molecular Biology 41 671-675.
60. Jenster G, Trapman J & Brinkmann AO 1993 Nuclear import of the human androgen receptor. Biochemical Journal 293 761-768.
61. Jeong BC, Hong CY, Chattopadhyay S, Park JH, Gong EY, Kim HJ, Chun SY & Lee K 2004 Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Molecular Endocrinology 18 13-25.
62. Jung C, Kim RS, Zhang HJ, Lee SJ & Jeng MH 2004 HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Research 64 9185-9192.
63. Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H & Muraguchi A 2000 Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochemical and Biophysical Research Communications 278 9-13.
64. Kang Z, Janne OA & Palvimo JJ 2004 Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Molecular Endocrinology 18 2633-2648.
65. Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM et al. 2004 Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene 23 6712-6725.
66. Knudsen KE, Arden KC & Cavenee WK 1998 Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. Journal of Biological Chemistry 273 20213-20222.
67. Knudsen KE, Cavenee WK & Arden KC 1999 D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Research 59 2297-2301.
68. Kotaja N, Aittomaki S, Silvennoinen O, Palvimo JJ & Janne OA 2000 ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation. Molecular Endocrinology 14 1986-2000.
69. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N & Ittmann M 2001 Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. PNAS 98 11563-11568.
70. Langley E, Kemppainen JA & Wilson EM 1998 Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. Journal of Biological Chemistry 273 92-101.
71. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML & Balk SP 2002 AR and ER interaction with a p21-activated kinase (PAK6). Molecular Endocrinology 16 85-99.
72. Lessard L, Begin LR, Gleave ME, Mes-Masson AM & Saad F 2005 Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. British Journal of Cancer 93 1019-1023.
73. Li P, Nicosia SV & Bai W 2001 Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. Journal of Biological Chemistry 276 20444-20450.
74. Li J, Fu J, Toumazou C, Yoon HG & Wong J 2005 A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Molecular Endocrinology 20 776-785.
75. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H & Chen JD 2003 Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. Journal of Biological Chemistry 278 5052-5061.
76. Lin HM, Zhao L & Cheng SY 2002 Is a ligand-independent co-repressor for thyroid hormone receptors. Journal of Biological Chemistry 277 28733-28741.
77. Lin DY, Fang HI, Ma AH, Huang YS, Pu YS, Jenster G, Kung HJ & Shih HM 2004a Negative modulation of androgen receptor transcriptional activity by Daxx. Molecular and Cellular Biology 24 10529-10541.
78. Lin HK, Hu YC, Lee DK & Chang C 2004b Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Molecular Endocrinology 18 2409-2423.
79. Loy CJ, Sim KS & Yong EL 2003 Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. PNAS 100 4562-4567.
80. Lu S, Tsai SY & Tsai MJ 1997 Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Research 57 4511-4516.
81. Maddison LA, Huss WJ, Barrios RM & Greenberg NM 2004 Differential expression of cell cycle regulatory molecules and evidence for a 'cyclin switch' during progression of prostate cancer. Prostate 58 335-344.
82. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
83. Marivoet S, Van Dijck P, Verhoeven G & Heyns W 1992 Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments. Molecular and Cellular Endocrinology 88 165-174.
84. Martinez ED & Danielsen M 2002 Loss of androgen receptor transcriptional activity at the G(1)/S transition. Journal of Biological Chemistry 277 29719-29729.
85. Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN & Balk SP 2004 Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Molecular Endocrinology 18 2388-2401.
86. McMahon C, Suthiphongchai T, DiRenzo J & Ewen ME 1999 P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. PNAS 96 5382-5387.
87. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M & Sellers WR 1999 Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Research 59 4291-4296.
88. Miyamoto H, Yeh S, Wilding G & Chang C 1998 Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. PNAS 95 7379-7384.
89. Narlikar GJ, Fan HY & Kingston RE 2002 Cooperation between complexes that regulate chromatin structure and transcription. Cell 108 475-487.
90. Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM & Ariga H 2003 DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Molecular Cancer Research 1 247-261.
91. Nishida T & Yasuda H 2002 PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. Journal of Biological Chemistry 277 41311-41317.
92. Paez J & Sellers WR 2003 PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treatment and Research 115 145-167.
93. Palvimo JJ, Reinikainen P, Ikonen T, Kallio PJ, Moilanen A & Janne OA 1996 Mutual transcriptional interference between RelA and androgen receptor. Journal of Biological Chemistry 271 24151-24156.
94. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P & Dahiya R 2000 Deletion of Y-chromosome specific-genes in human prostate cancer. Journal of Urology 163 1339-1342.
95. Petre CE, Wetherill YB, Danielsen M & Knudsen KE 2002 Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. Journal of Biological Chemistry 277 2207-2215.
96. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB & Knudsen KE 2003 Specificity of cyclin D1 for androgen receptor regulation. Cancer Research 63 4903-4913.
97. Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA & Knudsen KE 2004 A central domain of cyclin D1 mediates nuclear receptor co-repressor activity. Oncogene 24 431-444.
98. Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F, Harada S, Schmidt A, Rodan GA, Freedman LP et al. 2004 The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Molecular Endocrinology 18 2011-2023.
99. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ & Pestell RG 2001 Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Molecular Endocrinology 15 797-811.
100. Rigas AC, Ozanne DM, Neal DE & Robson CN 2003 The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway. Journal of Biological Chemistry 278 46087-46093.
101. Salesi N, Carlini P, Ruggeri EM, Ferretti G, Bria E & Cognetti F 2005 Prostate cancer: the role of hormonal therapy. Journal of Experimental and Clinical Cancer Research 24 175-180.
102. Schmidt D & Muller S 2003 PIAS/SUMO: new partners in transcriptional regulation. Cellular and Molecular Life Sciences 60 2561-2574.
103. Schrantz N, da Silva Correia J, Fowler B, Ge Q, Sun Z & Bokoch GM 2004 Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. Journal of Biological Chemistry 279 1922-1931.
104. Sengupta N & Seto E 2004 Regulation of histone deacetylase activities. Journal of Cellular Biochemistry 93 57-67.
105. Shang Y, Myers M & Brown M 2002 Formation of the androgen receptor transcription complex. Molecular Cell 9 601-610.
106. Sharma M & Sun Z 2001 5′TG3′ interacting factor interacts with Sin3A and represses AR-mediated transcription. Molecular Endocrinology 15 1918-1928.
107. Sharma M, Zarnegar M, Li X, Lim B & Sun Z 2000 Androgen receptor interacts with a novel MYST protein, HBO1. Journal of Biological Chemistry 275 35200-35208.
108. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K & Shemshedini L 2001 p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. Journal of Biological Chemistry 276 38472-38479.
109. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH & deVere White RW 2002 Complex functions of mutant p53 alleles from human prostate cancer. Prostate 51 59-72.
110. Shi XB, Candour-Edwards R, Beckett LA & Deitch AD 2004 A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value. BJU international 94 996-1002.
111. Shi S, Rui M, Han W, Wang Y, Qiu X, Ding P, Zhang P, Zhu X, Zhang Y, Gan Q et al. 2005 CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. International Journal of Biochemistry & Cell Biology 37 1633-1640.
112. Shou J, Ross S, Koeppen H, de Sauvage FJ & Gao WQ 2001 Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Research 61 7291-7297.
113. Silverstein RA & Ekwall K 2005 Sin3: a flexible regulator of global gene expression and genome stability. Current Genetics 47 1-17.
114. Sommer S & Fuqua SA 2001 Estrogen receptor and breast cancer. Seminars in Cancer Biology 11 339-352.
115. Song LN, Coghlan M & Gelmann EP 2004 Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Molecular Endocrinology 18 70-85.
116. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H & Cheng L 2004 Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clinical Cancer Research 10 5501-5507.
117. Taplin ME & Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry 91 483-490.
118. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al. 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (5748) 644-648.
119. Trapman J & Brinkmann AO 1996 The androgen receptor in prostate cancer. Pathology, Research and Practice 192 752-760.
120. Truica CI, Byers S & Gelmann EP 2000 Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Research 60 4709-4713.
121. Tsui KH, Chang PL, Lin HT & Juang HH 2004 Downregulation of the prostate specific antigen promoter by p53 in human prostate cancer cells. Journal of Urology 172 2035-2039.
122. Urnov FD & Wolffe AP 2001 Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 20 2991-3006.
123. Verrijdt G, Haelens A & Claessens F 2003 Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Molecular Genetics and Metabolism 78 (3) 175-185.
124. Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, Yeh S, Wu G, Guo Y & Chang C 2002 Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. Journal of Biological Chemistry 277 15426-15431.
125. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al. 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 209-221.
126. Wang L, Lin HK, Hu YC, Xie S, Yang L & Chang C 2004a Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. Journal of Biological Chemistry 279 32444-32452.
127. Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P & Chang C 2004b Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Molecular and Cell Biology 24 2202-2213.
128. Wen YD, Perissi V, Staszewski LM, Yang WM, Krones A, Glass CK, Rosenfeld MG & Seto E 2000 The histone deacetylase-3 complex contains nuclear receptor corepressors. PNAS 97 7202-7207.
129. Wilson JD 1996 Role of dihydrotestosterone in androgen action. Prostate Supplement 6 88-92.
130. Xia X, Lessor TJ, Zhang Y, Woodford N & Hamburger AW 2001 Analysis of the expression pattern of Ebp1, an ErbB-3-binding protein. Biochemical and Biophysical Research Communications 289 240-244.
131. Yang F, Li X, Sharma M, Zarnegar M, Lim B & Sun Z 2001 Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6. Journal of Biological Chemistry 276 15345-15353.
132. Yoon HG & Wong J 2005 The corepressors SMRT and N-CoR are involved in agonist- and antagonist-regulated transcription by androgen receptor. Molecular Endocrinology 5 1048-1060.
133. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J & Wong J 2003 Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO Journal 22 1336-1346.
134. Yu X, Li P, Roeder RG & Wang Z 2001 Inhibition of androgen receptor-mediated transcription by amino-terminal enhancer of split. Molecular and Cell Biology 21 4614-4625.
135. Yuan X, Lu ML, Li T & Balk SP 2001 SRY interacts with and negatively regulates androgen receptor transcriptional activity. Journal of Biological Chemistry 276 46647-46654.
136. Zhang Y, Fondell JD, Wang Q, Xia X, Cheng A, Lu ML & Hamburger AW 2002 Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene 21 5609-5618.
137. Zhang Y, Yang Y, Yeh S & Chang C 2004 ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation. Molecular and Cell Biology 24 1044-1057.
138. Zhang Y, Akinmade D & Hamburger AW 2005a The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription. Nucleic Acids Research 33 6024-6033.
139. Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A & Hamburger AW 2005b The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. PNAS 102 9890-9895.
140. Zhou ZX, Sar M, Simental JA, Lane MV & Wilson EM 1994 A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. Journal of Biological Chemistry 269 13115-13123.
141. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG et al. 2006 Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124 615-629.
142. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ & Bernards R 1998 Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes and Development 12 3488-3498.